RFA-NS-25-023: HEAL Initiative Studies to Enable Analgesic Discovery (R61/R33, Clinical Trial Not Allowed)

RFA-NS-25-023: HEAL Initiative Studies to Enable Analgesic Discovery (R61/R33, Clinical Trial Not Allowed)

Key details

The date context matters because this opportunity remains relevant for your target years 2026 and 2027. The posted page was opened in 2024, and the next NIH review cycle date points to multiple open rounds in 2026 and 2027 with final expiration in 2026/2027. For planning, this means you should treat it as an active federal research opportunity rather than a historical archived program.

1) What this NOFO is really about

This is a focused preclinical pipeline opportunity under NIH’s HEAL (Helping to End Addiction Long-term) Initiative. It is explicitly built to de-risk early translational steps toward safer pain treatments. The key intent is to support studies that improve the evidence base for later-stage therapeutic development, especially when the project can produce stronger assay, target, and validation outputs than a standard academic proposal.

The NOFO is aimed at investigators who are trying to move a candidate forward but are stuck before or at the early preclinical inflection point. In NIH language, this is the stage where mechanistic uncertainty is still high, but feasibility can be tested through assay development, compound selection, efficacy characterization, and translational planning.

The mechanism is not a classic single-phase grant. Instead, it is an R61/R33 phased model. In this structure, the early phase supports feasibility and method development, and a second phase is intended to scale toward more confidence in downstream development readiness. The same proposal can plan for both phases together but must treat milestones carefully and avoid overlap in phase timing.

Because the NOFO says clinical trials are not allowed, applicants should present a clear non-clinical translational package. This is non-negotiable for successful compliance and review. If you plan interventional work in humans, this NOFO is not the right fit; it is best used for assay and target validation, model and model-to-human translation planning, candidate filtering, and similar non-clinical work that supports the pain field pipeline.

2) Who should consider applying and who should skip

This opportunity is broad by organization type but narrow by intent.

Eligible organizations are wide-ranging among U.S. entities (higher-ed, nonprofits, businesses, local/federal entities, and certain U.S. governmental and community categories). But scope limitations are strict for foreign participation: non-domestic organizations are not eligible as lead applicants, and foreign components can only appear as components under the NIH rules.

Also, because this is not limited to a single institution type, team composition can be robust. You can apply through universities, mission-driven nonprofits, or commercial groups when they can produce a strong translational package. However, this breadth does not lower the scientific bar. The proposal still has to speak directly to analgesic discovery and therapeutic relevance.

Skip this NOFO if:

• You need a clinical trial budget and patient enrollment timeline.
• You want exploratory basic science with no clear path toward candidate or platform advancement.
• Your organization is not eligible to register in required systems on time.
• You cannot provide a clear two-stage plan with measurable gates.

A strong signal is whether your idea can produce high-confidence, actionable output that informs the “go/no-go” transition toward more advanced development.

3) Funding mechanics, review logic, and what that means for your proposal

The page reports an estimated total commitment of $2,500,000 for 4–5 awards in FY 2025, with funds tied to NIH appropriations and merit. In practical terms, this means this is a competitive and limited pool, not a broad open-invitation call with guaranteed award rates.

Important mechanics:

• Budget is capped at up to $350,000 in direct costs per year.
• Total project duration cannot exceed three years for the combined R61/R33 package.
• Phase durations are capped so that the early and late phase each stay within the NOFO’s constraints.
• No cost-sharing is required.

The review process follows NIH criteria and gives weight to both scientific quality and whether your plan can execute with rigor. Factor scores include significance, innovation, approach, feasibility, and alignment with program-specific goals. Reviewers evaluate whether your methods are strong enough for later-stage translation, whether milestones are measurable, and whether your team has the right combination of preclinical pharmacology, assay development, and translational context.

Because this is a HEAL NOFO with clinical relevance, additional review focus includes assay robustness, reproducibility, candidate selection logic, and the quality of your therapeutic discovery pathway. In short, it is less about “this is a good scientific idea” and more about “this is a feasible and defensible step on the development path.”

4) Official schedule and why 2026/2027 matters

The key dates section lists recurring cycles with review and award timelines. For your planning in the target years:

• September 17, 2026 is a submission date (with later review/advisory and start alignment)
• January 15, 2027 is the next major submission date
• Expiration is listed as January 16, 2027

Because this NOFO is part of a recurring annual opportunity pattern, teams can target one of the windows that best matches readiness. For 2026 and 2027, the practical reading is:

• If your project can be submitted with minimal late-stage adjustments, target September 2026.
• If your evidence package needs one more round of internal prework, use the January 2027 window.

It is safer to submit early within the window. NIH explicitly advises correction windows before the hard due time (5:00 PM local time). Missing due-time due to submission errors is risky and often irreversible.

5) Eligibility and compliance details to verify first

Before drafting text, teams should run an eligibility matrix before grant writing:

1. Organization registration checklist

• SAM active registration must be complete.
• eRA Commons registration and PI affiliation details must be correct.
• Grants.gov registration must be complete.

Your team should complete this at least six weeks before the target date. The NIH notices in this NOFO family are strict: late registrations are not valid grounds for late submission.

2. Clinical trials confirmation The NOFO says clinical trials are not allowed. Write your science plan and specific aims around non-clinical models, preclinical assay development, and translational science that supports later development.

3. PI and organizational credentials

• Every PI/S must have active eRA Commons status.
• The organization must have complete, consistent UEI, SAM, and organizational credentials.

4. IP and collaboration complexity There is a required intellectual property strategy attachment (2-page max). If licensing or external proprietary compounds are involved, plans for rights, freedom to operate, and joint ownership governance must be explicit.

5. Team structure and capacity The NOFO strongly encourages multidisciplinary teams in relevant cases (statistics, translational pharmacology, biologists, assay specialists, drug development specialists), especially where milestones move from mechanism to validated candidate-level evidence.

6) What a high-quality application should contain

Given the explicit review expectations, your narrative should be built as if your reviewers are checking for decisions and reproducibility, not style.

A) Research strategy and significance

• State the pain indication and the problem you will solve in one paragraph.
• Show why current therapeutics are insufficient for the stated indication.
• Explain why your target/mechanism lowers the risk of adding new opioid exposure versus current treatment approaches.

B) R61 and R33-specific aims

• Use the required headings: R61 phase specific aims and R33 phase specific aims.
• Separate milestones and go/no-go logic.

A strong structure is:

• R61: establish assay validity, compound quality triage, model relevance, and initial target engagement.
• R33: deepen validation and mechanistic support to support transition decisions.

C) Milestones and decision points

Reviewers specifically check whether milestone criteria are clear, measurable, and linked to decision gates. Avoid aspirational wording without hard thresholds.

Strong options:

• Define assay performance thresholds for specificity/sensitivity.
• Set pre-registered criteria for candidate selection.
• Include failure pathways (what happens if lead candidate misses expected profile).

D) Data strategy and transparency

HEAL data expectations are strong, including study registration expectations and platform reporting discipline. Include a realistic plan for data standards, repository workflows, and publication readiness (including publication openness requirements and required acknowledgements).

E) Team and environment

Applications are judged on investigator expertise and institutional fit. Match your team profiles directly to execution risk:

• Who can execute assay design?
• Who can interpret model endpoints?
• Who can solve failure modes?
• Who handles translational package quality and regulatory-facing documentation?

7) Suggested 12–20 week execution roadmap for US applicants

Whether you are aiming for September 2026 or January 2027, this order matters:

Weeks 1–3

• Confirm internal eligibility and registrations.
• Assign PI and institutional contacts.
• Map required forms and deadlines.

Weeks 3–6

• Draft full scientific strategy and specific aims.
• Confirm assay and candidate pathway from internal advisors.

Weeks 6–9

• Build evaluation plan with milestone gates and measurable criteria.
• Draft budget with transparent year-by-year direct costs under $350k/year.
• Start IP review and conflict checks.

Weeks 9–12

• Build compliance section (human subjects/animal welfare if applicable, study registrations, resources).
• Prepare required attachments, including IP strategy and letters if licensed materials are involved.
• Internal dry-run peer review against NIH criteria.

Weeks 13–16

• Finalize and submit a pre-submission mock via your submission portal.
• Correct errors before final deadline and leave correction buffer.

Weeks 16–20

• Submit early, then track eRA status.
• Keep correction windows open and monitor warnings.

8) Common mistakes that lower reviewability

This section is not generic; each item maps to recurrent NIH compliance patterns:

• Missing required registration(s) or mismatched UEI/organization IDs.
• Forgetting the required R61/R33 heading separation in specific aims.
• Underdeveloped milestone logic that does not define success criteria.
• Vague translational pathway with no clear bridge toward drug discovery readiness.
• Weak IP plan when compounds or biologics are central.
• Not addressing assay rigor elements: randomization, blinding, and reproducibility in preclinical workflows where relevant.
• Submitting with preventable form errors that force last-minute corrections and reduce review confidence.

9) FAQ: decision-relevant points

Is this opportunity only for pain programs already in trials?

No. Clinical trials are explicitly disallowed. This is for preclinical translational work that enables future development.

Is this one award only?

No. The NOFO lists a total funding estimate and anticipated 4–5 awards. Exact number and outcomes depend on merit and appropriations.

Do nonprofits need matching funds?

No cost sharing is required according to this NOFO.

Can a for-profit company apply?

For-profit entities are listed as eligible organization types under the applicant categories, but your science and execution model still must fit HEAL goals.

Can you apply as a foreign university?

As a lead applicant, non-domestic entities are not eligible. U.S. entities can include foreign components only under NIH policy.

What should we do if we miss a filing window?

Target the next listed due date if available. The schedule is recurring within this NOFO, but watch final expiration.

10) What is strong enough for this NOFO in 2026/2027

The strongest proposals usually have one clear property: they remove uncertainty from one stage of the pain-treatment pathway. That can be by improving assay reliability, by providing stronger characterization for a therapeutic modality, or by reducing translation ambiguity from model to mechanism.

Because the NOFO explicitly expects rigor and milestone-based progress, it rewards projects that do not just describe excellent science but demonstrate disciplined execution planning. That means:

• A realistic scope (do not overspecify when your budget and timeline cannot support it)
• Hard criteria for advancing or stopping candidate paths
• A clear team plan with translational communication and decision documentation
• Data sharing and publication behavior considered from project start

11) Official links

• Primary NOFO page: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-023.html
• HEAL program page: https://heal.nih.gov/
• NIH funding systems overview and forms: https://grants.nih.gov/
• Grants application information: https://grants.nih.gov/grants/how-to-apply.htm
• HEAL data and sharing requirements (latest notices): https://heal.nih.gov/

12) Final assessment for practical planning

This is a legitimate 2026/2027-relevant federal funding channel for teams with strong non-clinical pain research and a realistic development pathway. It is suitable for applicants who can deliver assay quality, clear milestones, and reproducible translational plans rather than broad, unfocused discovery narratives.

In plain terms: this is best for teams that can convert a mechanism into validated, actionable preclinical evidence and are prepared for strict NIH submission and review discipline.